CR665

CR665 is a peripheral kappa-opioid receptor agonist that is currently under development for the treatment of pain, inflammation, and pruritus (itching). It is being developed by Cara Therapeutics, a biopharmaceutical company based in the United States.

History

CR665 was first synthesized by Cara Therapeutics in the early 2000s as part of their research into peripheral kappa-opioid receptor agonists. The drug is currently in the clinical trial phase, with studies focusing on its potential use in treating pain, inflammation, and pruritus.

Mechanism of Action

CR665 works by binding to and activating the kappa-opioid receptors located in the peripheral nervous system. This action is believed to produce analgesic, anti-inflammatory, and anti-pruritic effects without the central nervous system side effects commonly associated with other opioid drugs.

Clinical Trials

Several clinical trials have been conducted to evaluate the safety and efficacy of CR665. These trials have shown promising results, with the drug demonstrating significant pain relief and reduction in inflammation and pruritus in a variety of patient populations.

Potential Uses

CR665 has potential uses in a variety of medical conditions. These include chronic pain, osteoarthritis, rheumatoid arthritis, postoperative pain, dermatitis, and other conditions characterized by pain, inflammation, and pruritus.

Side Effects

As with all drugs, CR665 has the potential to cause side effects. However, due to its peripheral action, it is expected to have fewer side effects than traditional opioid drugs. The most common side effects reported in clinical trials include nausea, vomiting, and constipation.

Future Developments

Cara Therapeutics continues to investigate the potential uses of CR665. Future developments may include further clinical trials and potential approval for use in various medical conditions.

CR665 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia